MeiraGTx GAAP EPS of -$0.62 misses by $0.13, revenue of $0.41M misses by $6.56M
Source: SeekingAlpha
2025-11-13 12:10:01 ET
More on MeiraGTx
- MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential
- MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital
- Eli Lilly in pact with MeiraGTx to develop gene therapies for eye diseases
- Seeking Alpha’s Quant Rating on MeiraGTx
- Historical earnings data for MeiraGTx
Read the full article on Seeking Alpha
For further details see:
MeiraGTx GAAP EPS of -$0.62 misses by $0.13, revenue of $0.41M misses by $6.56M
MeiraGTx Holdings plc
NASDAQ: MGTX
MGTX Trading
-3.98% G/L:
$7.47 Last:
257,785 Volume:
$7.68 Open:
MGTX Latest News
March 26, 2026 08:00:00 am
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
February 17, 2026 09:05:00 am
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
MGTX Stock Data
$607,706,212
74,454,072
4.21%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
